XILIO THERAPEUTICS INC
XLO
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Xilio Therapeutics is a clinical-stage biotechnology company developing tumor-selective immunotherapies for cancer. The company’s research and development process involves preclinical animal testing, a standard but exclusionary practice in the pharmaceutical industry. According to its SEC filings, Xilio’s operations are subject to regulations including the Animal Welfare Act, indicating the use of animals in its long-term preclinical studies. Cruelty Free Investors classifies Xilio Therapeutics under its “Animal Testing” category, identifying the company as one that exploits animals for commercial research purposes.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.